Parkinson's disease is related to a deficiency of complex I bioenergetic activity that may be etiologic and likely contributes to increased oxidative stress. The protein chemical work described here addresses the question inherent to other parts of this Udall proposal, i.e., """"""""As Complex I activity is clearly reduced in Parkinson's Disease, based on several studies, is this altered functioning caused by disrupted assembly and/or altered stability, AND/OR is there post-translational oxidative modification of the complex that progressively inhibits functioning? Project 3 will address three Aims.
Specific Aim 1 : Complete technique development and establish hot spots of oxidative modification of Complex I. While we have made considerable progress in identifying the sites of oxidative damage in Complex I by peroxynitrite, we need to fully identify sites of modification by hydroxyl radical reaction. Also, we wish to develop an antibody that can detect tryptophan oxidation to facilitate identification of this modification.
Specific Aim 2 : Further characterization of the phosphorylation/dephosphorylation of Complex I. We have established that three subunits of Complex I are phosphorylated and there is evidence that these modifications affect activity. Recent work has identified a rare genetic form of Parkinson's disease due to mutation of a mitochondrial protein kinase. Thus, altered phosphorylation/dephosphorylation may be a factor in the altered Complex I functioning which is evident in PD. We plan to identify the phosphorylation sites on Complex I by mass spectrometry and evaluate the functional significance of each.
Specific Aim 3 : Analysis of Complex I in PD brains and the cell lines created by protofection technology in Dr. Bennett's project. We have developed the tools for analyzing the levels of Complex I, its activity and the assembly state in small amounts of mitochondria. We will use these techniques to evaluate the properties of Complex I in PD brains and cell lines, and appropriate controls. These same samples will also be analyzed for oxidative, post-translational modifications that could account for altered functioning of Complex I.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS039788-06A1
Application #
6962407
Study Section
Special Emphasis Panel (ZNS1-SRB-M (12))
Project Start
2005-04-01
Project End
2010-03-31
Budget Start
2005-04-01
Budget End
2006-04-30
Support Year
6
Fiscal Year
2005
Total Cost
$191,401
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Cronin-Furman, Emily N; Borland, M Kathleen; Bergquist, Kristen E et al. (2013) Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression. Mol Neurodegener 8:6
Iyer, S; Xiao, E; Alsayegh, K et al. (2012) Mitochondrial gene replacement in human pluripotent stem cell-derived neural progenitors. Gene Ther 19:469-75
Thomas, Ravindar R; Keeney, Paula M; Bennett, James P (2012) Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex. J Parkinsons Dis 2:67-76
Thomas, Ravindar R; Khan, Shaharyar M; Smigrodzki, Rafal M et al. (2012) RhTFAM treatment stimulates mitochondrial oxidative metabolism and improves memory in aged mice. Aging (Albany NY) 4:620-35
Barrett, Matthew J; Wylie, Scott A; Harrison, Madaline B et al. (2011) Handedness and motor symptom asymmetry in Parkinson's disease. J Neurol Neurosurg Psychiatry 82:1122-4
Thomas, Ravindar R; Khan, Shaharyar M; Portell, Francisco R et al. (2011) Recombinant human mitochondrial transcription factor A stimulates mitochondrial biogenesis and ATP synthesis, improves motor function after MPTP, reduces oxidative stress and increases survival after endotoxin. Mitochondrion 11:108-18
Young, Kisha J; Bennett, James P (2010) The mitochondrial secret(ase) of Alzheimer's disease. J Alzheimers Dis 20 Suppl 2:S381-400
Trimmer, Patricia A; Schwartz, Kathleen M; Borland, M Kathleen et al. (2009) Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy. Mol Neurodegener 4:26
Keeney, Paula M; Quigley, Caitlin K; Dunham, Lisa D et al. (2009) Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 20:897-907
Harrison, Madaline B; Wylie, Scott A; Frysinger, Robert C et al. (2009) UPDRS activity of daily living score as a marker of Parkinson's disease progression. Mov Disord 24:224-30

Showing the most recent 10 out of 39 publications